Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites.
When sustained-release adhesive and non-adhesive microspheres which release the same drugs at similar rates are administered orally, drug absorption after administration of adhesive microspheres should, if the gastrointestinal residence of adhesive microspheres is prolonged as a result of mucoadhesion, be higher than that after administration of non-adhesive microspheres. The gastrointestinal transit of oral adhesive microspheres in man has been evaluated pharmacokinetically using furosemide and riboflavin, compounds with limited absorption sites in the upper small intestine. In a preliminary experiment with fasted rats it was confirmed that a higher percentage of the drug remained in the stomach and that plasma drug levels were higher when furosemide was administered in the form of adhesive rather than non-adhesive microspheres. Two kinds of sustained-release microsphere, adhesive and non-adhesive, containing furosemide and riboflavin in hard gelatin capsules were prepared and orally administered to 10 healthy fasted volunteers in a cross-over design. Areas under the plasma concentration-time curves (AUC) were 1.8 times larger for furosemide and urinary recovery was 2.4 times higher for riboflavin when adhesive microspheres rather than when non-adhesive microspheres were used. When adhesive microspheres containing riboflavin were administered to fed volunteers, urinary recovery was 2.1 times higher and mean residence time (MRT) was more prolonged than when the microspheres were administered to fasted volunteers. Adhesive microspheres were found to adhere to the gastric or intestinal mucosa with high affinity in man and rats, resulting in prolonged gastrointestinal residence.
Akiyama
Y
Y
DDS Research Laboratories, Pharmaceutical Research Division, Takeda Chemical Industries Ltd, Osaka, Japan.
Nagahara
N
N
Nara
E
E
Kitano
M
M
Iwasa
S
S
Yamamoto
I
I
Azuma
J
J
Ogawa
Y
Y
D000269:Adhesives / Q000008:administration & dosage* / Q000378:metabolism*; D000284:Administration, Oral; D000328:Adult; D000818:Animals; D003692:Delayed-Action Preparations; D004232:Diuretics / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004435:Eating / Q000502:physiology; D005665:Furosemide / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D008863:Microspheres; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012256:Riboflavin / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D000269:Adhesives; D003692:Delayed-Action Preparations; D004232:Diuretics; D017319:Photosensitizing Agents; D005665:Furosemide; D012256:Riboflavin